In this multicenter study, the authors reviewed the results obtained in patients who underwent Gamma Knife radiosurgery (GKRS) for dural arteriovenous fistulas (dAVFs) and determined predictors of outcome.
Data from a cohort of 114 patients who underwent GKRS for cerebral dAVFs were compiled from the International Gamma Knife Research Foundation. Favorable outcome was defined as dAVF obliteration and no posttreatment hemorrhage or permanent symptomatic radiation-induced complications. Patient and dAVF characteristics were assessed to determine predictors of outcome in a multivariate logistic regression analysis; dAVF-free obliteration was calculated in a competing-risk survival analysis; and Youden indices were used to determine optimal radiosurgical dose.
A mean margin dose of 21.8 Gy was delivered. The mean follow-up duration was 4 years (range 0.5–18 years). The overall obliteration rate was 68.4%. The postradiosurgery actuarial rates of obliteration at 3, 5, 7, and 10 years were 41.3%, 61.1%, 70.1%, and 82.0%, respectively. Post-GRKS hemorrhage occurred in 4 patients (annual risk of 0.9%). Radiation-induced imaging changes occurred in 10.4% of patients; 5.2% were symptomatic, and 3.5% had permanent deficits. Favorable outcome was achieved in 63.2% of patients. Patients with middle fossa and tentorial dAVFs (OR 2.4, p = 0.048) and those receiving a margin dose greater than 23 Gy (OR 2.6, p = 0.030) were less likely to achieve a favorable outcome. Commonly used grading scales (e.g., Borden and Cognard) were not predictive of outcome. Female sex (OR 1.7, p = 0.03), absent venous ectasia (OR 3.4, p < 0.001), and cavernous carotid location (OR 2.1, p = 0.019) were predictors of GKRS-induced dAVF obliteration.
GKRS for cerebral dAVFs achieved obliteration and avoided permanent complications in the majority of patients. Those with cavernous carotid location and no venous ectasia were more likely to have fistula obliteration following radiosurgery. Commonly used grading scales were not reliable predictors of outcome following radiosurgery.
Correspondence David J. McCarthy: University of Miami Miller School of Medicine, Miami, FL. firstname.lastname@example.org.
INCLUDE WHEN CITING Published online January 4, 2019; DOI: 10.3171/2018.8.JNS181467.
Disclosures Dr. Vargo reports receiving a speaking honorarium from BrainLAB. Dr. Hideyuki Kano reports receiving an Elekta AB research grant. Dr. Grills reports stock ownership in Greater Michigan Gamma Knife and is on the executive board of directors for Greater Michigan Gamma Knife. Dr. Lunsford reports direct stock ownership in Elekta AB; he is a consultant for Insightec.
Cohen-InbarOStarkeRMPaisanGKanoHHuangPPRodriguez-MercadoR: Early versus late arteriovenous malformation responders after stereotactic radiosurgery: an international multicenter study. J Neurosurg127:503–5112017
PatibandlaMRDingDKanoHStarkeRMLeeJYKMathieuD: Effect of treatment period on outcomes after stereotactic radiosurgery for brain arteriovenous malformations: an international multicenter study. J Neurosurg[epub ahead of print February 2 2018. DOI: 10.3171/2017.8.JNS171336]
TonettiDAGrossBAJankowitzBTKanoHMonacoEAIIINiranjanA: Reconsidering an important subclass of high-risk dural arteriovenous fistulas for stereotactic radiosurgery. J Neurosurg[epub ahead of print March 16 2018. DOI: 10.3171/2017.10.JNS171802]